Abstract
Background: While the role of cisplatin HIPEC added to cytoreductive surgery in stage III epithelial ovarian cancer in improving outcomes becomes more clear, in vivo data on pharmacokinetics and -dynamics are lacking. Furthermore, factors such as the impact of hyperthermia remain to be defined. Here, we report in vivo tumor uptake of cisplatin of patient enrolled in the OvIP study (NCT02567253), a multicenter randomized trial investigating tumor tissue platinum penetration after normothermic (37°C) versus hyperthermic (41°C) chemoperfusion with cisplatin at 75 or 120 mg/m2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
